阿扎胞苷联合大剂量阿糖胞苷和米托蒽醌治疗高危急性髓系白血病的1期研究
这项1期研究在高危急性髓系白血病(包括复发/难治)患者中,于大剂量阿糖胞苷和米托蒽醌前给予阿扎胞苷表观遗传预激,主要目标是确定2期推荐剂量。46例患者(中位年龄66岁)接受剂量递增,总缓解率61%,30天诱导死亡率为2.2%,推荐2期剂量为阿扎胞苷75 mg/m2第1-5天。
要点
- 阿扎胞苷联合HiDAC/米托蒽醌的推荐2期剂量为75 mg/m2第1-5天。
- 总缓解率61%,30天诱导死亡率2.2%。
- 有利ELN风险、NPM1或IDH2突变者更可能缓解,TP53突变者较少缓解。
核心结论
- 阿扎胞苷表观遗传预激后给予HiDAC/米托蒽醌在高危AML中可行,推荐2期剂量为阿扎胞苷75 mg/m2第1-5天。
研究设计与样本
- 1期剂量递增研究,46例高危AML患者(含复发/难治),中位年龄66岁。
- 阿扎胞苷37.5、50或75 mg/m2皮下或静脉每日一次第1-5天,随后第6天和第10天各一次HiDAC 3000 mg/m2和米托蒽醌30 mg/m2(老年受试者HiDAC/米托蒽醌剂量减少33%)。
主要发现
- 发生2例剂量限制性毒性(同一患者):50 mg/m2剂量下急性肝衰竭和肾损伤。
- 30天诱导死亡率为2.2%(46例中1例)。
- 总缓解率(包括完全缓解和血细胞计数未完全恢复的完全缓解)为61%(46例中28例)。
- ≥60岁初治的治疗相关AML和原发AML患者比由前驱血液病(骨髓增生异常综合征和慢性粒单核细胞白血病)进展的未治疗AML患者更可能缓解。
- 有利欧洲白血病网络风险(P = .008)、NPM1突变(P = .007)或IDH2突变(P = .03)者更可能缓解,TP53突变者(P = .03)较少缓解。
关键数值与推荐
- 推荐2期剂量:阿扎胞苷75 mg/m2每日第1-5天,随后第6天和第10天各一次HiDAC 3000 mg/m2和米托蒽醌30 mg/m2。
临床怎么用
- 在高危AML(包括复发/难治)中可考虑阿扎胞苷预激后HiDAC/米托蒽醌方案,推荐2期剂量为阿扎胞苷75 mg/m2第1-5天。
- 治疗选择时可参考ELN风险、NPM1、IDH2和TP53突变状态预测缓解可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this phase 1 study, azacitidine (AZA) was given before high-dose cytarabine (HiDAC) and mitoxantrone (mito) based on the hypothesis that epigenetic priming with a hypomethylating agent before cytotoxic chemotherapy would improve response rates in patients with high-risk acute myeloid leukemia (AML), including relapsed/refractory disease. The primary objective was to establish the recommended phase 2 dose of AZA given before standard HiDAC/mito. In a dose escalation scheme, 46 patients (median age, 66 years) received AZA at 37.5, 50, or 75 mg/m2 subcutaneously or IV once daily on days 1 to 5 followed by HiDAC (3000 mg/m2) and mitoxantrone (30 mg/m2) once each on days 6 and 10 (the HiDAC/mito dose was reduced 33% in elderly subjects). Two dose-limiting toxicities occurred (both in the same patient): acute liver failure and kidney injury at the 50 mg/m2 dose. The 30-day induction death rate was 2.2% (1 of 46). The overall response rate, including complete remission and complete remission with incomplete count recovery, was 61% (28 of 46). Previously untreated patients aged ≥60 years with therapy-related AML and de novo AML were more likely to respond than untreated patients with AML progressing from an antecedent hematologic disorder (myelodysplastic syndrome and chronic myelomonocytic leukemia). Patients with favorable European Leukemia Network risk (P = .008), NPM1 mutations (P = .007), or IDH2 mutations (P = .03) were more likely to respond, and those with TP53 mutations (P = .03) were less likely to respond. The recommended phase 2 dose of AZA is 75 mg/m2 per day on days 1 to 5 followed by HiDAC (3000 mg/m2) and mitoxantrone (30 mg/m2) once each on days 6 and 10. This trial was registered at www.clinicaltrials.gov as #NCT01839240.
引用
- Cahill KE, Karimi YH, Karrison TG, et al. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020. PMID: 32074275. doi:10.1182/bloodadvances.2019000795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。